top of page |
Type and details of transgene |
Is the transgene Plasmodium derived |
Transgene: not Plasmodium |
Transgene name | PH domain of human phospholipase Cδ1 (hPLCδ1) fused to YFP and CFP |
top of page |
Details of the genetic modification |
Inducable system used | No |
Additional remarks inducable system |
|
Type of plasmid/construct | Circular plasmid |
PlasmoGEM (Sanger) construct/vector used | No |
Modified PlasmoGEM construct/vector used | No
|
Plasmid/construct map |
|
Plasmid/construct sequence |
|
Restriction sites to linearize plasmid |
|
Selectable marker used to select the mutant parasite | tgdhfr |
Promoter of the selectable marker | pbdhfr |
Selection (positive) procedure | pyrimethamine |
Selection (negative) procedure | No |
Additional remarks genetic modification | The mutant expresses a fusion protein consisting of the PH domain of human phospholipase Cδ1 (hPLCδ1) fused to yellow fluorescent protein (YFP) and cyan fluorescent protein (CFP).
A P. berghei expression cassette was generated, in which the strong constitutive eef1α promoter controls expression of a fusion protein consisting of the PH domain of hPLCδ1 fused to YFP (C-terminal) and CFP (N-terminal). A vector containing this reporter cassette, together with a tgdhfr/ts selection marker for antimalarial drug resistance, was then introduced into P. berghei schizonts by electroporation, and maintained as episome by selecting for the resistance marker.
The PH domain of human phospholipase Cδ1 (hPLCδ1) fused to CFP and YFP was isolated from a pcDNA3.1(+)-based plasmid containing the CYPHR fusion protein (Violin et al., 2003) as a HindIII/XbaI fragment and subsequently blunted. The P. berghei expression vector pDEFGFPM3A encodes the green fluorescent protein (GFP) and is equivalent to MR4 reagent MRA-786 (pL0017) differing from the pPbGFPCON (Franke-Fayard et al., 2004) only by the presence of an additional XbaI site immediately following the stop codon of gfp. The gfp coding sequence was removed by a BamHI/XbaI digest, the vector blunted and the CFP–PH–YFP sequence inserted. |
Additional remarks selection procedure | |
top of page |
Other details transgene |
top of page |
Promoter |
Gene Model of Parasite |
PBANKA_1133300
|
Gene Model P. falciparum ortholog |
PF3D7_1357100
|
Gene product | elongation factor 1-alpha |
Gene product: Alternative name | eef1a |
Primer information details of the primers used for amplification of the promoter sequence
Primer information details of the primers used for amplification of the promoter sequence
Sequence Primer 1 | |
Additional information primer 1 | |
Sequence Primer 2 | |
Additional information primer 2 | |
|
|
top of page |
3'-UTR |
Gene Model of Parasite |
PBANKA_0719300
|
Gene product | bifunctional dihydrofolate reductase-thymidylate synthase, putative |
Gene product: Alternative name | dhfr/ts |
Primer information details of the primers used for amplification the 3'-UTR sequences
Primer information details of the primers used for amplification the 3'-UTR sequences
Sequence Primer 1 | |
Additional information primer 1 | |
Sequence Primer 2 | |
Additional information primer 2 | |
|
|
Insertion/Replacement locus |
Replacement / Insertion | Not available |
Gene Model of Parasite |
Not available
|
Gene product | Not available |
Gene product: Alternative name | |
Primer information details of the primers used for amplification of the target sequences
Primer information details of the primers used for amplification of the target sequences
Sequence Primer 1 | |
Additional information primer 1 | |
Sequence Primer 2 | |
Additional information primer 2 | |
Sequence Primer 3 | |
Additional information primer 3 | |
Sequence Primer 4 | |
Additional information primer 4 | |
|
|
top of page |